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Among bloodstream methicillin-resistant Staphylococcus
aureus (MRSA) isolates from adult patients in a single hos-
pital, susceptibility to co-trimoxazole increased progres-
sively from 31% in 1988 to 92% in 1997 (p<0.0001). If also
observed in other institutions, these findings should
encourage the performance of a clinical trial of sufficient
size to compare co-trimoxazole to vancomycin in treating
MRSA infections.
M
ethicillin-resistant  Staphylococcus aureus (MRSA)
is a growing medical concern. During the last 2
decades, the rates of infections caused by MRSAincreased
among hospitalized patients in most developed countries
(1). The aim of this study was to examine trends in antibi-
otic resistance of hospital-acquired bloodstream MRSA
isolates from 1988 to 1997 in our institution.
The Study
Included in the analysis were all patients >18 years of
age who had hospital-acquired bacteremia caused by S.
aureus.  The study took place at Rabin Medical Center,
Beilinson Campus, Petach-Tikva, Israel, a 900-bed univer-
sity hospital. Our center serves an urban population of
approximately 1 million persons as both a first-line and
tertiary facility. A prospective surveillance of all bac-
teremic episodes occurring at our medical center is per-
formed continuously and, since 1988, has been incorporat-
ed into a computerized database for bacteremia. Episodes
of bacteremia are detected by daily surveillance of the
microbiology laboratory records, with an annual range of
700 to 900 episodes.
Antibiotic susceptibility was tested by using the disk
diffusion technique on Mueller-Hinton agar, according to
the procedures established by the National Committee for
Clinical Laboratory Standards (NCCLS) (2). Plates were
incubated at 30ºC for 18 h and 40 h for methicillin (5
µg/disk) and at 37°C for 18 h for other antibiotics.
Bacteremia was considered to be hospital-acquired if it
appeared 48 h after admission. 
During the study period, a total of 944 episodes of S.
aureus bacteremia were documented. We found 598 (63%)
hospital-acquired episodes, with an annual number of
episodes ranging from 35 to 121. Among the hospital-
acquired episodes, 270 (45%) were due to MRSA strains.
During the recent decade, rates of resistance to methicillin
were high but stable among the hospital-acquired isolates,
ranging from 25% to 57%. Rates of susceptibility to co-tri-
moxazole among patients with hospital-acquired MRSA
increased significantly from 31% in 1988 to 92% in 1997
(p=0.0001) (Figure). 
The hospital-acquired MRSA isolates were persistently
highly resistant to chloramphenicol (69% in 1988 and
100% in 1997; p=NS), gentamicin (89% in 1988 to 94% in
1997; p=NS), and ciprofloxacin (87% in 1988 to 96% in
1997; p=NS). The resistance to clindamycin (62% in 1988
to 92% in 1997; p=0.04), fusidic acid (6% in 1988 to 14%
in 1997; p=0.03), and rifampicin (21% in 1988 to 76% in
1997; p=0.02) increased significantly. All isolates were
sensitive to vancomycin.
Conclusions
Our study shows that 92% of nosocomial MRSAstrains
were sensitive to co-trimoxazole in 1997 as compared with
31% in 1988. Several factors may have influenced the
emergence of co-trimoxazole–sensitive MRSA, including
the reduced usage of this drug in our institution. According
to the pharmacy records, usage of co-trimoxazole in our
institution decreased progressively from 28 daily doses per
1,000 hospital days in 1990 to 17 daily doses per 1,000
1168 Emerging Infectious Diseases • Vol. 9, No. 9, September 2003
DISPATCHES
*Rabin Medical Center, Beilinson Campus, Petach-Tikvah, Israel;
and †Schneider Children’s Medical Center of Israel, Petach-
Tikvah, Israel
Figure. Co-trimoxazole susceptibility among methicillin-resistant
Staphylococcus aureus. Columns indicate percentage of hospital-
acquired methicillin-resistant S. aureus (MRSA) susceptible to co-
trimoxazole. Numbers on top of the columns are absolute numbers
of hospital-acquired MRSA susceptible to co-trimoxazole.hospital days in 1997 (3). Arecent multicenter report from
several Belgian hospitals showed an increase in co-trimox-
azole susceptibility among MRSAisolates (4). These find-
ings are in contrast with trends of increasing resistance of
S. aureus to a variety of anti-staphylococcal drugs other
than co-trimoxazole, since the beginning of the antibiotic
era. These trends had culminated recently with the appear-
ance of glycopeptide resistance in hospitals and methicillin
resistance in the community (5). Whether our findings
reflect an increase of co-trimoxazole–sensitive MRSA
clone/s in our institution needs further exploration. In set-
tings where co-trimoxazole is extensively used, a substan-
tial increase of MRSA resistance to co-trimoxazole has
been observed. For example, Martin et al. described a seri-
al cross-sectional study of resistance to co-trimoxazole
among all clinical isolates of S. aureus and other
Enterobacteriaceae  during a 16-year period at San
Francisco General Hospital (6). In this study, resistance to
co-trimoxazole increased from 0% to 48% in S. aureus iso-
lates obtained from HIV-infected patients. The authors
explained this increase of resistance to co-trimoxazole by
the extensive use of this drug as prophylaxis against
Pneumocystis carinii pneumonia.
Eventually, our data may favor the use of co-trimoxazole
as a potentially cost-effective antimicrobial drug for treating
MRSA infections. Co-trimoxazole has been shown to be
effective against MRSA both in vitro and in vivo in mice
(7), as well as in clinical reports on meningitis, septicemia,
and endocarditis (8–9). A controlled comparative trial of
intravenous co-trimoxazole versus intravenous vancomycin
in 101 cases of severe S. aureus infections in intravenous
drug users was conducted by Markowitz et al. (10) in 1992.
The authors reported 100% cure rates for either drug in
MRSA infections, including bacteremia. More recently,
Stein et al. showed varying degrees of success in treating
with co-trimoxazole orthopedic implant infections caused
by S. aureus (11). Unfortunately, this study did not distin-
guish MRSA from methicillin-sensitive S. aureus strains. 
Recent in vitro data have shown good activity of co-tri-
moxazole against clinical isolates of vancomycin-interme-
diate  S. aureus (12–13) and vancomycin-resistant S.
aureus (14). In some of these cases, co-trimoxazole in
combination with surgical debridement and other anti-
staphylococcal drugs has been used successfully (12,14).
In clinical practice, cyclical usage of co-trimoxazole and
vancomycin and possible other newer anti-MRSA drugs
such as oxazolidinones and streptogramins may prove of
value in slowing down rates of development of antibiotic
resistance in MRSA. The in vitro–presented results, if con-
firmed in other institutions, in conjunction with anecdotal
clinical data, should encourage the performance of a clini-
cal trial of sufficient size to compare co-trimoxazole to
vancomycin in treating MRSA infections. 
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